Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Cash from Operations: 2019-2025

Historic Cash from Operations for Eton Pharmaceuticals (ETON) over the last 7 years, with Sep 2025 value amounting to $12.0 million.

  • Eton Pharmaceuticals' Cash from Operations rose 307.38% to $12.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.3 million, marking a year-over-year increase of 904.71%. This contributed to the annual value of $969,000 for FY2024, which is 85.78% down from last year.
  • Eton Pharmaceuticals' Cash from Operations amounted to $12.0 million in Q3 2025, which was up 51.10% from $8.0 million recorded in Q2 2025.
  • In the past 5 years, Eton Pharmaceuticals' Cash from Operations registered a high of $12.0 million during Q3 2025, and its lowest value of -$5.1 million during Q4 2021.
  • For the 3-year period, Eton Pharmaceuticals' Cash from Operations averaged around $2.7 million, with its median value being $1.3 million (2024).
  • Its Cash from Operations has fluctuated over the past 5 years, first spiked by 766.94% in 2022, then tumbled by 297.67% in 2024.
  • Over the past 5 years, Eton Pharmaceuticals' Cash from Operations (Quarterly) stood at -$5.1 million in 2021, then soared by 155.50% to $2.8 million in 2022, then tumbled by 86.37% to $387,000 in 2023, then slumped by 297.67% to -$765,000 in 2024, then soared by 307.38% to $12.0 million in 2025.
  • Its Cash from Operations stands at $12.0 million for Q3 2025, versus $8.0 million for Q2 2025 and $2.1 million for Q1 2025.